We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-25.4%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.39B
AUM Growth
-$1.3B
Cap. Flow
-$296M
Cap. Flow %
-12.4%
Top 10 Hldgs %
47.64%
Holding
157
New
7
Increased
9
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$25.4M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$20.3M
3
VIGL
Vigil Neuroscience
VIGL
+$14.8M
4
IGMS
IGM Biosciences
IGMS
+$9.31M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.83M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$18.8M
2
NG icon
NovaGold Resources
NG
+$17.8M
3
ALBO
Albireo Pharma Inc
ALBO
+$14M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.7M
5
KRYS icon
Krystal Biotech
KRYS
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 90.67%
2 Consumer Discretionary 6.64%
3 Financials 0.85%
4 Consumer Staples 0.31%
5 Industrials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$55.1B
$185M 7.76%
587,500
+87,500
+18% +$25.4M
WW
2
DELISTED
WW International
WW
$152M 6.35%
14,818,300
– –
LXRX icon
3
Lexicon Pharmaceuticals
LXRX
$1.03B
$149M 6.23%
71,178,364
– –
ONC
4
BeOne Medicines Ltd
ONC
$33.9B
$125M 5.25%
665,000
-10,000
-1% -$2.13M
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$111M 4.65%
1,350,000
-50,000
-4% -$5.11M
ALNY icon
6
Alnylam Pharmaceuticals
ALNY
$38.5B
$106M 4.44%
650,000
– –
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$93.6M 3.92%
650,000
+150,000
+30% +$20.3M
FATE icon
8
Fate Therapeutics
FATE
$267M
$77.5M 3.25%
2,000,000
+200,000
+11% +$7.74M
SEER icon
9
Seer Inc
SEER
$115M
$72.4M 3.03%
4,750,000
– –
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$66.2M 2.77%
1,650,000
+64,951
+4% +$2.72M
BLU
11
DELISTED
BELLUS Health Inc.
BLU
$58.5M 2.45%
8,500,000
– –
IGMS
12
DELISTED
IGM Biosciences
IGMS
$53.5M 2.24%
2,000,000
+500,000
+33% +$9.31M
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$52.5M 2.2%
1,500,000
– –
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
$48M 2.01%
850,000
– –
KYMR icon
15
Kymera Therapeutics
KYMR
$8.65B
$42.3M 1.77%
1,000,000
– –
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
$37.9M 1.59%
4,000,000
-2,000,000
-33% -$18.8M
CYTK icon
17
Cytokinetics
CYTK
$10.8B
$36.8M 1.54%
1,000,000
– –
KRYS icon
18
Krystal Biotech
KRYS
$10.7B
$33.3M 1.39%
500,000
-200,000
-29% -$12.5M
SRRK icon
19
Scholar Rock
SRRK
$5.88B
$31.6M 1.32%
2,450,000
– –
ERAS icon
20
Erasca
ERAS
$6.13B
$27.3M 1.14%
3,172,221
– –
FHTX icon
21
Foghorn Therapeutics
FHTX
$288M
$26.2M 1.1%
1,720,720
– –
SAGE
22
DELISTED
Sage Therapeutics
SAGE
$24.8M 1.04%
750,000
-250,000
-25% -$9.4M
SDGR icon
23
Schrodinger
SDGR
$1.12B
$23.9M 1%
700,000
– –
RLAY icon
24
Relay Therapeutics
RLAY
$3.99B
$21M 0.88%
700,000
-50,000
-7% -$1.21M
GBIO
25
DELISTED
Generation Bio
GBIO
$20.7M 0.86%
281,419
– –
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2022 Portfolio in Review

As of Q1 2022, Artal Group held 157 positions worth $2.39B, down 35% from $3.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group withdrew a net $296M in Q1 2022, closing 20 positions and reducing 11 holdings. Its most notable exit was NovaGold Resources, an estimated $17.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Financials.

Against the trend, Artal Group opened a new position in Vigil Neuroscience worth $7.88M.

  • Artal Group's largest Q1 2022 buy was Vigil Neuroscience: 1,121,191 shares worth $7.88M.
  • Artal Group added most to argenx in Q1 2022, an estimated $25.4M increase.
  • Artal Group's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $18.8M.
  • Artal Group fully exited NovaGold Resources in Q1 2022, selling an estimated $17.8M.
  • Artal Group's ten largest holdings make up 48% of its $2.39B portfolio in Q1 2022.
  • Artal Group opened 7 new positions and closed 20 in Q1 2022.
  • Artal Group's portfolio value fell 35% quarter-over-quarter to $2.39B.

Based on Artal Group's 13F filing for Q1 2022, filed 12 May 2022.